Beijing Hospital
Beijing, Beijing Municipality, 100730, China
Location status: Recruiting
NCT Number: NCT07479641
This study will investigate the bioequivalence between two formulations of HRS-1893 tablets. Safety and tolerability will also be assessed.
Interested in participating?
Request Info18 year–55 year
All sexes
Interventional
Phase 1
Beijing, Beijing Municipality, 100730, China
Location status: Recruiting
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Test formulation of HRS-1893 tablet, oral.
Reference formulation of HRS-1893 tablet, oral.
Time frame: From Day 1 to Day 17.
Primary Pharmacokinetic (PK) parameters of different HRS-1893 formulations in healthy subjects.
Time frame: From Day 1 to Day 17.
Primary Pharmacokinetic (PK) parameters of different HRS-1893 formulations in healthy subjects.
Time frame: From Day 1 to Day 17.
Primary pharmacokinetic (PK) parameters of different HRS-1893 formulations in healthy subjects.
Time frame: From Day 1 to Day 17.
Other primary pharmacokinetic (PK) parameters of different HRS-1893 formulations in healthy subjects.
Time frame: From Day 1 to Day 17.
Other primary pharmacokinetic (PK) parameters of different HRS-1893 formulations in healthy subjects.
Time frame: From Day 1 to Day 17.
Other primary pharmacokinetic (PK) parameters of different HRS-1893 formulations in healthy subjects.
Time frame: From Day 1 to Day 17.
Other primary pharmacokinetic (PK) parameters of different HRS-1893 formulations in healthy subjects.
Time frame: From Day 1 to Day 21 ± 2.
Safety and tolerability of different HRS-1893 formulations in healthy subjects.
Time frame: From Day 1 to Day 21 ± 2.
Safety and tolerability of different HRS-1893 formulations in healthy subjects.
Time frame: From Day 1 to Day 21 ± 2.
Safety and tolerability of different HRS-1893 formulations in healthy subjects.
Time frame: From Day 1 to Day 21 ± 2.
Safety and tolerability of different HRS-1893 formulations in healthy subjects.
Contact information is provided by the study sponsor or research team.
Shandong Suncadia Medicine Co., Ltd.
Industry
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07674758
Becker Muscular Dystrophy, Cardiomyopathies
Sacramento, California, United States
View Trial DetailsNCT07617844
Cardiomyopathies, Cardiomyopathy
Hangzhou, Zhejiang, China
View Trial DetailsNCT01143454
Arterial Occlusive Diseases, Arteriosclerosis
Washington D.C., District of Columbia, United States
View Trial DetailsNCT07116525
Arrhythmias, Cardiac, Atrial Fibrillation
Bruges, Belgium
View Trial Details